1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Clinical characteristics of patients in training and test groups^{^a}
Clinical Characteristics Separate Patient Group to Train Readers (n = 20) Patient Group to Test Diagnostic Accuracy
Recurrent Tumor (n = 28) Posttreatment Change (n = 35) P Value
Male/female ratio 12:8 18:10 29:6 .105
Age (mean) (yr) 55 ± 10 60 ± 11 58 ± 12 .452
Primary site 
    Nasopharynx 5 (25) 6 (21) 9 (26) 
    Oral cavity 6 (30) 11 (39) 11 (31) 
    Oropharynx 4 (20) 5 (18) 5 (14) 
    Larynx/hypopharynx 2 (10) 3 (11) 4 (11) 
    PNS 3 (15) 3 (11) 6 (17) 
Treatment modality .183
    OP 10 (50) 13 (46) 12 (34) 
    CCRT 8 (45) 13 (46) 16 (45) 
    OP + RT 2 (10) 2 (7) 7 (20) 
Mean time interval (range)^{^b} 28 (12–35) 27 (12–60) 24 (10–41) .518
Final diagnosis 
    Pathologic exam 18 7 
    Clinical follow-up 10 28 
Note:—CCRT indicates concurrent chemoradiation therapy; NA, not applicable; OP, operation; PNS, paranasal sinus; RT, radiation therapy.
↵a Numbers in parentheses are percentages except where noted.
↵b Mean time interval is expressed as months and the period between the end of treatment and MR imaging.